FP7-Programa de trabajo Cooperaci - PowerPoint PPT Presentation

1 / 32
About This Presentation
Title:

FP7-Programa de trabajo Cooperaci

Description:

FP7-Programa de trabajo Cooperaci n: Salud-2012 Dra. Mar a Alejandra Alvarez malvarez_at_conicet.gov.ar * * Contexto Objetivo: Incentivar la investigaci n e ... – PowerPoint PPT presentation

Number of Views:35
Avg rating:3.0/5.0
Slides: 33
Provided by: allo6
Category:

less

Transcript and Presenter's Notes

Title: FP7-Programa de trabajo Cooperaci


1
FP7-Programa de trabajo Cooperación Salud-2012
  • Dra. María Alejandra Alvarez
  • malvarez_at_conicet.gov.ar

2
Contexto
  • Objetivo Incentivar la investigación e
    innovación dirigidas a enfrentar los grandes
    desafíos actuales.
  • Herramientas para alcanzar este objetivo
  • Financiamiento de tópicos que permitan
    desarrollar productos, procesos y servicios
    nuevos y más innovadores (incluyendo actividades
    piloto, demostración y validación)
  • Identificación y apoyo a la capacidad de
    innovación y diseminación.
  • Promoción del uso del conocimiento generado.
  • La comisión proveerá asistencia a los consorcios
    para acceder a los instrumentos financieros
    adecuados (por ejemplo eventos de brokerage con
    inversores)

3
Contexto (2)
  • Énfasis en la participación de pequeñas y
    medianas empresas (PyMEs) con un mayor foco en el
    sector de las tecnologías médicas.
  • Apoyo a la investigación colaborativa de gran
    calidad cubriendo requisitos de excelencia
    científica, administración profesional de fondos
    y alto impacto socio-económico.
  • Presupuesto 620 millones.
  • Gran interrelación entre las temáticas.

4
Temas clave
  • Envejecimiento activo y saludable (tecnología
    médica, enfermedades crónicas, sistemas de salud,
    ensayos clínicos, recolección de datos),
  • Investigación relevante para las PyMEs ( aprox.
    50 de los tópicos, p.ej. tecnologías médicas.
    Se espera así el desarrollo de nuevas
    tecnologías, nuevas drogas y nuevas terapias para
    mejorar la calidad de vida),
  • Tecnologías médicas (transplante de órganos,
    órganos artificiales, diagnóstico de enfermedades
    infecciosas, discapacidades sensoriales, manejo
    de la diabetes, enfermedad inflamatoria crónica),
  • Enfermedades raras (nuevas tecnologías de
    diagnóstico y tratamiento y nuevas drogas, uso de
    las ómicas, desarrollo clínico y preclínico de
    drogas huérfanas),
  • Ensayos clínicos (ensayos clínicos destinados a
    la optimización del tratamiento de los adultos
    mayores, medicinas para la diabetes pediátrica y
    adolescente, drogas huérfanas para el tratamiento
    de enfermedades raras)
  • Acciones de diseminación (estimulación de la
    formación de una red que promueva al
    transferencia de conocimiento en actividades
    financiadas por el FP)

5
Cooperación internacional
  • Todos los tópicos están abiertos a la cooperación
    internacional con los terceros países.
  • Desafíos globales.
  • Enfermedades de la pobreza.
  • Enfermedades raras.
  • Mejora de la competitividad a través de la
    cooperación internacional.
  • Apoyo de las relaciones con la UE.
  • Reconociendo la apertura del NIH a investigadores
    europeos los grupos de USA son elegibles para
    recibir financiamiento.

6
Enfoques temáticos cruzados
  • Hay enfoques cruzados con los temas de
  • Tecnologías de las comunicaciones (ICT)
  • Alimentación, Agricultura, Pesca y Biotecnología
    (KBBE)
  • Ciencias Sociales y Humanas (SSH)

7
A destacar!
  • 620 millones.
  • Dos llamados
  • FP7-HEALTH-2012-INNOVATION-1 con un presupuesto
    de 546 millones
  • FP7-HEALTH-2012-INNOVATION-2 llamado piloto con
    un presupuesto de 108 millones y condiciones
    muy específicas (sección III)
  • Presentación en dos etapas.
  • Al menos 50 de los temas están dirigido a las
    PyMEs.
  • Un numero de socios mayor del número mínimo de
    participantes debe estar justificado,
    especificando la importancia que tiene para
    alcanzar los objetivos propuestos.
  • Aspectos éticos (tanto en la metodología como en
    las posibles implicaciones de los resultados. Ver
    Guía del Aplicante).
  • Uso de animales en investigación (Protocolo de
    protección y bienestar de animales, Principio de
    las 3R reducción, refinamiento y reemplazo).
  • Cuestión de género (participación balanceada de
    hombres y mujeres).
  • Impacto socio-económico de la investigación.
  • Esquemas de financiación (ajustarse a los
    esquemas a los que se presentan es un criterio de
    elegibilidad).

8
Los tres pilares del programa de trabajo en la
prioridad temática SALUD
  1. Biotecnología, herramientas genéricas y
    tecnología médica para salud humana.
  2. Investigación translativa para salud humana.
  3. Optimización del servicio de cuidado de la salud
    a ciudadanos europeos.

9
1. Biotecnología, herramientas genéricas y
tecnología médica para salud humana.
  • 1.1 Cerrado en 2012
  • 1.2 Detección, diagnóstico y monitoreo.
    Desarrollo de herramientas y tecnologías para la
    visualización, detección y análisis de imágenes
    dirigido a investigación biomédica, predicción,
    diagnóstico, monitoreo y prognosis de
    enfermedades y para dar apoyo y guía a
    intervenciones terapéuticas. Enfoque hacia la
    multidisciplinariedad que involucre biología
    molecular y celular, fisiología, genética,
    física, química, ingeniería biomédica,
    nanotecnologías, microsistemas, tecnologías de
    dispositivos e información. Se enfatiza el uso de
    métodos no, o mínimamente, invasivos.
  • 1.3 Cerrado en 2012
  • 1.4 Enfoques e intervenciones terapéuticas
    innovadoras. Tema central transplantes. Tópicos
    subsidiarios en cooperación internacional en stem
    cells y transferencia de AN). Todos los temas
    requieren de realización de ensayos clínicos y
    participación de PyMEs. Mejoramiento de técnicas
    de transplante y para la mejor inmunotolerancia
    con menos efectos colaterales. Tecnologías
    médicas, tanto para transplante de órganos
    sólidos como para células y tejidos. Puede
    incluir el trabajo con órganos artificiales. El
    uso de AN provee la base para aplicaciones
    terapéuticas y profilácticas en vacunas,
    transferencia de genes, inmunomodulación y RNAi)

10
1.2 Detección, diagnóstico y monitoreo.
  • HEALTH.2012.1.2.-1 Development of technologies
    with a view to patient group stratification for
    personalised medicine applications
    FP7-HEALTH-2012-INNOVATION-1.
  • The aim of this topic is to support research and
    development and/or proof of principle of
    technologies for application in the area of
    personalised medicine, i.e. tailored medical
    interventions which are more effective and have
    fewer undesirable adverse effects in specifically
    defined patient groups. These technologies should
    be of use for research, screening, diagnostics
    and/or guidance of therapeutic interventions. The
    projects must include quality control aspects for
    data generated and where appropriate use
    statistical tools. Potential end-users should
    actively be included in the project, at least for
    proof of principle projects. Note Limits on the
    EU financial contribution apply. These are
    implemented strictly as formal eligibility
    criteria.
  • Funding scheme SME-targeted Collaborative
    Project (medium-scale focused research project)
  • Requested EU contribution per project Maximum
    EUR 6 000 000
  • One or more proposals can be selected.
  • Expected impact The development of new and
    improved tools and technologies will contribute
    to enabling the uptake of personalised medicine
    into clinical practice and support the
    competitiveness of Europe in this area. The
    applications are expected to advance research in
    personalised medicine and have an impact in the
    relevant industry (in particular for SMEs).
  • Specific feature SME-targeted research is
    designed to encourage SME efforts towards
    research and innovation. Priority will be given
    to proposals demonstrating that research
    intensive SMEs play a leading role. The projects
    will be led by SMEs with RD capacities but the
    coordinator does not need to be an SME. The
    expected project results should clearly be of
    interest and potential benefit to SME(s).
  • Additional eligibility criterion Projects will
    only be selected for funding on the condition
    that the estimated EU contribution going to
    SME(s) is 30 or more of the total estimated EU
    contribution for the project as a whole. This
    will be assessed at the end of the negotiation,
    before signature of the grant agreement.
    Proposals not fulfilling this criterion will not
    be funded.

11
1.4 Enfoques e intervenciones terapéuticas
innovadoras.
  • HEALTH.2012.1.4.-1 Innovative approaches to
    solid organ transplantation FP7-HEALTH-2012-INN
    OVATION-1.
  • The aim of this topic is the practical
    exploitation of recent research findings to
    improve the outcome, increase efficiency or widen
    the scope of solid organ transplantation.
    Projects are required to include clinical work
    and the necessary regulatory work as appropriate.
    Full attention needs to be paid to safety and
    immunological aspects of the work. Research
    should be translational, and may include
    improvement of understanding of mode of action if
    needed. For projects on xenotransplantation, if
    the work is not yet ready for clinical
    application, proposals should include a reasoned
    plan indicating the main development and
    regulatory steps needed to move the technology to
    the clinic. Research should involve European
    industry, in particular the SME sector. Note
    Limits on the EU financial contribution apply.
    These are implemented strictly as formal
    eligibility criteria.
  • Funding scheme Collaborative Project
    (medium-scale focussed research project)
    Requested EU contribution per project Maximum
    EUR 6 000 000 One or more proposals can be
    selected.
  • Expected impact Results should lead to improved
    treatment outcome for transplantation patients,
    better understanding of mode of action of
    treatments or potential treatments and be of use
    to the industrial, especially SME, sector.
  • Additional eligibility criterion Projects will
    only be selected for funding on the condition
    that the estimated EU contribution going to
    SME(s) is 15 or more of the total estimated EU
    contribution for the project as a whole. This
    will be assessed at the end of the negotiation,
    before signature of the grant agreement.
    Proposals not fulfilling this criterion will not
    be funded.

12
  • HEALTH.2012.1.4.-2 Medical technology for the
    transplantation sector and bioartificial organs
    FP7-HEALTH-2012-INNOVATION-2.
  • Work on transplantation may involve the use of
    cells, tissues or organs. Work on bioartificial
    organs should take into account the fact that
    these are composed of both biological and
    artificial components.
  • Funding scheme Collaborative project (small or
    medium-scale focused research project). One or
    more proposals can be selected.
  • Expected impact Results should lead to
    development of new tools, technologies or devices
    for use in transplantation and for replacing
    essential organ function by bioartificial organs.
  • Specific feature
  • Specific SME innovation initiative designed to
    encourage stronger SME efforts towards research
    and innovation.
  • SMEs will need to have a leading role in the
    project.
  • Applicants invited to present a full proposal
    for stage 2 are requested to submit a detailed
    exploitation plan clearly describing the
    valorisation of the technology to be developed.
  • Expected project results should be of clear
    interest and potential benefit to SME(s).
  • Additional eligibility criteria The requested EU
    contribution per project should depend on the
    needs of the project and
  • shall not exceed a maximum of EUR 6 000 000. The
    proposed project duration indicated in the
    proposal should be up to 3 years. Projects will
    only be selected for funding on the condition
    that the estimated EU contribution to SME(s) is
    50 or more of the total estimated EU
    contribution to the whole project. This will be
    assessed at the end of the negotiation, before
    signature of the grant agreement. Proposals not
    fulfilling this criterion will not be funded. The
    financial viability of all partners in projects
    needs to fulfil the Commission requirements. This
    will be checked at the stage 2 evaluation.
  • Number of participants minimum 3 up to maximum
    5, established in at least three different EU
    Member States or Associated Countries.
    Participation is restricted to entities
    established in EU Member States and Associated
    Countries. Any project activity must be performed
    by an entity in the EU Member States or
    Associated Countries (see also section III).
    SME(s) need to be 1) at least 51 owned and
    controlled by one or more individuals who are
    citizens of one of the EU Member States or
    Associated Countries or permanent residents in
    one of those countries, or 2) at least 51 owned
    and controlled by another business concern that
    is itself at least 51 owned and controlled by
    individuals who are citizens of, or permanent
    residents in those countries..

13
  • HEALTH.2012.1.4-3 Innovative strategies for
    translation of stem cell based therapies in
    regenerative medicine (European Union-Australia
    cooperation). FP7-HEALTH-2012-INNOVATION-1.
  • Projects should aim to develop innovative
    strategies to stem cell-based therapies based on
    various approaches including allogeneic and/or
    autologous sources, with an emphasis on
    understanding the mechanisms of action and nature
    of the host response. Proposals should include
    thorough characterisation, quality control of the
    product(s), efficacy and safety in relevant
    pre-clinical models and, if possible, early
    assessment in humans or relevant bridging
    studies. The selected project should capitalise
    on the strong expertise and synergistic
    opportunities available in Australia and Europe
    in the fields of stem cell biology, cell-host
    interactions, and bioengineering, bio-processing
    and clinical trial management. Therapeutic
    products and clinical protocols should be
    developed through collaboration with industry
    partners and in consultation with appropriate
    regulatory bodies and health economic advisors.
    Part of the research project will be conducted by
    Australian researchers in Australia while the
    other part would be conducted by collaborative
    partners in the EU. ()
  • Note Limits on the EU financial contribution
    apply. These are implemented strictly as formal
    eligibility criteria.
  • Funding scheme SME-targeted Collaborative
    Project (medium-scale focused research project)
    Requested EU contribution per project Maximum
    EUR 6 000 000 Only up to one proposal can be
    selected.
  • Expected impact The main impact of this work
    should be the extent to which new, innovative
    therapeutic approaches for these diseases can be
    tested in relevant preclinical models or humans.
    Projects are expected to lead to closer
    cooperation between the EU and Australia in the
    stem cell research field.

14
  • HEALTH.2012.1.4-4 Targeted nucleic acid delivery
    as an innovative therapeutic or prophylactic
    approach. FP7-HEALTH-2012-INNOVATION-1
  • The aim of this research is to exploit technology
    for nucleic acid delivery through testing in
    clinical trials carried out within the lifetime
    of the project. Recent innovative developments in
    DNA vaccination, immunotherapy, gene therapy or
    RNA interference are very encouraging but remain
    challenging and more proof-of-principle is
    needed. Any justified disease or disorder may be
    targeted. Detailed safety, immunogenicity,
    toxicity and feasibility studies in a preclinical
    setup (animal models) should preferably be
    already available or addressed before the
    beginning of the project. The necessary
    regulatory work should be included as
    appropriate. Proposals should develop
    multidisciplinary and translational research with
    potential for exploitation by the clinical and/or
    industrial sectors. Active participation by SMEs
    (minimum 30 of the EC contribution to the
    budget) is required and this will be considered
    in the evaluation of the proposal. Note Limits
    on the EU financial contribution apply. These are
    implemented strictly as formal eligibility
    criteria.
  • Funding scheme SME-targeted Collaborative
    project (medium-scale focused research project)
    One or more proposals can be selected.
  • Expected impact Building on recent results the
    project should link promising emerging
    technologies with clinical application in the
    area of nucleic acid delivery for prophylactic or
    therapeutic purposes. This would enhance European
    expertise and competitiveness in an important
    emerging market. Research will also support the
    European biotechnology industry, especially the
    SME sector.
  • Specific feature SME-targeted research is
    designed to encourage SME efforts towards
    research and innovation. Priority will be given
    to proposals demonstrating that research
    intensive SMEs play a leading role. The projects
    will be led by SMEs with RD capacities but the
    coordinator does not need to be an SME. The
    expected project results should clearly be of
    interest and potential benefit to SME(s).
  • Additional eligibility criteria
  • Requested EU contribution per project Maximum
    EUR 6 000 000
  • Projects will only be selected for funding on the
    condition that the estimated EU contribution
    going to SME(s) is 30 or more of the total
    estimated EU contribution for the project as a
    whole. This will be assessed at the end of the
    negotiation, before signature of the grant
    agreement. Proposals not fulfilling this
    criterion will not be funded.

15
2. Investigación translativa para salud humana.
  • 2.1 Integrating Biological Data and Processes
    Large-scale data gathering, System biology
  • 2.1.1 Large-scale data gathering
  • 2.1.2 System biology
  • 2.2 Research on the brain and related diseases,
    human development and ageing
  • 2.2.1 Closed on 2012
  • 2.2.2 Human development and ageing
  • 2.3 Translational research in major infectious
    diseases to confront major threats to public
    health
  • 2.3.0 Cross-cutting
  • 2.3.2 HIV/AIDS, malaria and tuberculosis
  • 2.4 Translational research in other major
    diseases
  • 2.4.3 Diabetes and obesity
  • 2.4.4 Rare diseases
  • 2.4.5 Other chronic diseases

16
2.1 Integrating Biological Data and Processes
Large-scale data gathering, System biology
  • 2.1.1 Large-scale data gathering
  • HEALTH.2012.2.1.1-1 Omics for rare diseases.
    Projects funded under this heading should
    contribute towards the ambitious 2020 goals of
    the International Rare Diseases Research
    Consortium (IRDiRC) 200 new therapies for rare
    diseases (orphan drugs) and diagnostics tests for
    all rare diseases.
  • HEALTH.2012.2.1.1-1-A Support for international
    rare disease research. FP7-HEALTH-2012-INNOVATION-
    1.
  • HEALTH.2012.2.1.1-1-B Clinical utility of -omics
    for better diagnosis of rare diseases.
    FP7-HEALTH-2012-INNOVATION-1.
  • HEALTH.2012.2.1.1-1-C Databases, biobanks and
    'clinical bio-informatics' hub forrare diseases.
    FP7-HEALTH-2012-INNOVATION-1.
  • HEALTH.2012.2.1.1-2 Validation of -omics-based
    biomarkers for diseases affecting the elderly.
    (1)
  • HEALTH.2012.2.1.1-3. Statistical methods for
    collection and analysis of -omics data. (1)
  • 2.1.2 System biology
  • HEALTH.2012.2.1.2-1. Systems medicine SME-driven
    research applying systems biology approaches to
    address medical and clinical needs. (1)
  • HEALTH.2012.2.1.2-2. Systems medicine Applying
    systems biology approaches for understanding
    complex human diseases and their co-morbidities.
    (1)
  • HEALTH.2012.2.1.2-3 Preparing for the future
    research and innovation activities in systems
    medicine. (1)

17
2.2 Research on th brain and related diseases,
human development and ageing
  • 2.2.2 Human development and ageing
  • Research on the basic mechanisms of development
    and ageing is required to improve health and
    quality of life during the life course through
    the use of a wide variety of methodologies and
    tools aimed at better understanding the processes
    of life-long development and healthy ageing,
    preventing and curing a series of the most common
    age-related diseases.
  • HEALTH.2012.2.2.2-1 Integrative systems biology
    and comparative genomics for studying human
    ageing and/or most common age-related
    diseases.(1)
  • Expected impact Projects are expected to
    translate knowledge to humans and contribute
    directly to bio-gerontology. By studying the
    interactions between genetic, epigenetic and
    environmental factors, and how these give rise to
    the ageing phenotype in health and disease, the
    project(s) should improve the lives of older
    people.
  • HEALTH.2012.2.2.2.-2 Investigator-driven
    clinical trials for optimisation of management of
    elderly patients with multiple diseases. (1)
  • The aim of the projects should be the comparison
    of outcomes of various treatment regimens for
    those diseases that are most common in elderly
    populations.

18
2.3 Translational research in major infectious
diseases to confront major threats to public
health
  • 2.3.0 Cross-cutting
  • HEALTH.2012.2.3.0-1 Diagnostics for infectious
    diseases in humans. FP7-HEALTH-2012-INNOVATION-2.
    This topic covers the development and/or
    validation of diagnostic tests for infectious
    diseases with the aim of meeting real clinical
    and public health needs.
  • Funding scheme Collaborative project (small or
    medium-scale focused research project). One or
    more proposals can be selected.
  • Expected impact Projects should deliver new or
    improved diagnostic tools which will lead to more
    appropriate patient management in the clinical
    setting and/or help reducing the spread of
    infections of global importance.
  • HEALTH.2012.2.3.0-2 ERA-NET on infectious
    diseases. FP7-ERANET-2012-RTD
  • 2.3.2 HIV/AIDS, malaria and tuberculosis
  • The focus will be on promoting translational
    research aiming at bringing basic knowledge
    through to clinical application in developing new
    therapies, diagnostic tools and vaccines for
    HIV/AIDS, malaria and tuberculosis.
  • HEALTH.2012.2.3.2-1 Co-infection of HIV/AIDS,
    malaria, tuberculosis and/or hepatitis. (1)
  • HEALTH.2012.2.3.2-2 Co-morbidity between
    infectious and non-communicable diseases. (1)
  • HEALTH.2012.2.3.2-3 Prevention and treatment for
    HIV/AIDS, malaria and tuberculosis. (1)
  • HEALTH.2012.2.3.2-4 Low-cost interventions for
    disease control in resource poor settings. (1)

19
2.4 Translational research in other major
diseases
  • 2.4.3 Diabetes and obesity
  • For both diabetes and obesity, special attention
    will be given to juvenile diseases and factors
    operating in childhood. Considering the reduction
    in life expectancy resulting from these diseases,
    particular attention should be given to
    paediatric aspects, whenever possible.
  • HEALTH.2012.2.4.3-1 Innovative approach to
    manage diabetes. (1)
  • HEALTH.2012.2.4.3-2 Investigator-driven clinical
    trials for type 1 diabetes research. (1)
  • 2.4.4 Rare diseases
  • For this call for proposals the topics will focus
    on the preclinical and clinical development of
    orphan drugs, and on the conduction of
    observational trials for those rare diseases
    treated offlabel, aiming to improve clinical
    practices in the management of these diseases.
    These efforts will be complemented with
    coordination action activities aimed at
    identifying and exchanging best practices in the
    clinical management of rare diseases.
  • HEALTH.2012.2.4.4-1 Preclinical and/or clinical
    development of substances with a clear potential
    as orphan drugs. (1)
  • HEALTH.2012.2.4.4-3 Best practice and knowledge
    sharing in the clinical management of rare
    diseases. (1)

20
2.4 Translational research in other major diseases
  • 2.4.5 Other chronic diseases
  • For this call for proposals the focus will be on
    non-lethal diseases and chronic conditions with a
    high impact on the quality of life at old age
    such as functional and sensory impairment and
    chronic inflammatory diseases. It is expected
    that collaborative research in this area will
    lead to improved diagnostics of the chronic
    conditions, develop tools and/or intervention
    strategies, which may contribute to delaying the
    onset of chronic diseases, their efficient
    treatment, and improving quality of life.
  • HEALTH.2012.2.4.5-1 Technological approaches to
    combating sensory impairments. FP7-HEALTH-2012-INN
    OVATION-2. Examples of possible areas to be
    considered strategies aiming at prevention of
    damage and rejuvenation of sensory cells and
    systems, treatment of sensory diseases,
    implantable devices, cell based approaches,
    including stem cells, and development of
    artificial organs or their parts. Full attention
    needs to be paid to
  • safety, bio-compatibility, interoperability and
    regulatory aspects as appropriate. Note Limits
    on the EU financial contribution apply. These are
    implemented strictly as formal eligibility
    criteria. Funding scheme Collaborative Project
    (small or medium-scale focused research project)
  • HEALTH.2012.2.4.5-2 Biomarkers and diagnostics
    for chronic inflammatory diseases of the joints
    and/or digestive system. (1)

21
3. Optimising the delivery of healthcare to
European citizen
  • 3.2 Quality, efficiency and solidarity of
    healthcare systems including transitional health
    systems
  • HEALTH.2012.3.2-1 Improving the organisation of
    health service delivery. (1)
  • HEALTH.2012.3.2-2 New methodologies for health
    technology assessment. (1)
  • HEALTH.2012.3.2-3 Social innovation for active
    and healthy ageing. (1)
  • 3.4 International Public health and Health
    systems
  • The specific cooperation actions in this area
    focus on the priorities agreed through
    bi-regional dialogues in third countries/regions
    and international fora, as well as within the
    context of Millennium Development Goals (MDGs).
    It has been long recognised at the global level
    that research is needed to improve the efficiency
    and effectiveness of health systems in many low
    and middle income countries. This call will focus
    on health systems/services research while at the
    same time strengthening research capacity
    building in terms of human resources. Note For
    the topic described below, applicants will have
    to follow the rules for two-stage submission
    procedure (see also respective call fiche in
    section III).
  • HEALTH.2012.3.4-1 Research on health systems and
    services in low- and middle income countries.
    FP7-HEALTH-2012-INNOVATION-1. Projects should
    allow national and regional decision makers to
    better translate knowledge, empirical data and
    operational experience into policies and planning
    for more effective, efficient and equitable
    health systems and services. Funding scheme
    Specific International Cooperation Action (SICA),
    Collaborative Project (small or medium-scale
    focused research project) target regions All
    international cooperation countries (ICPC)

22
4 Otras acciones
  • 4.1 Coordination and support actions across the
    theme
  • The objective of these actions is to contribute
    to the implementation of the Framework programme
    and the preparation of future European Union
    innovation, research and technological
    development policy.
  • For this call for proposals the focus of this
    area will be on technology transfer and
    dissemination of results.
  • HEALTH.2012.4.1-1 Network to encourage knowledge
    transfer activity in FP-funded health research
    (especially in academic and governmental
    organisations). (1)
  • HEALTH.2012.4.1-2 Training actions linked to
    intellectual property rights management and
    knowledge transfer. (1)
  • HEALTH.2012.4.1-3 Support for Presidency events
    Organisation of supporting actions and events
    related to the Presidency of the European Union.
    (1)
  • HEALTH.2012.4.1-4 Communicating the benefits of
    European research to the general public. (1)
  • HEALTH.2012.4.1-5 Preparing the future for
    health research and innovation. (1)
  • HEALTH.2012.4.1-6 Setting health-related
    development goals beyond 2015. (1)

23
(No Transcript)
24
(No Transcript)
25
(No Transcript)
26
Algunas Condiciones para los FP7-HEALTH-2012-INNOV
ATION-1
27
Evaluación- etapa 1
Criterio Umbral Mínimo
Calidad CyT 4/5
Impacto 3/5
Umbral total 8/10
  • Las evaluaciones serán realizadas por evaluadores
    externos
  • Los coordinadores de las propuestas que alcancen
    la etapa 1 serán invitados a enviar la propuesta
    completa (etapa 2) que luego será evaluada
    nuevamente en forma completa de acuerdo a los
    objetivos, criterios de eligibilidad, etc.
    Indicados en el programa de trabajo.

28
Evaluación- etapa 2
  • El deadline se indicará al momento de invitar a
    enviarla.
  • En línea con los objetivos de cada tópico se
    pueden agregar criterios de evaluación en la
    sección II del programa de trabajo
  • En el caso de los proyectos colaborativos con
    PYMEs es importante que se cumplan los
    requerimientos indicados en el programa de
    trabajo en cuanto a condiciones y del
    presupuesto que la UE destina a las PYMEs.
  • La PYME puede o no ser el coordinador del
    proyecto, lo que sí debe es tener un rol
    fundamental en la toma de decisiones referidas al
    management del proyecto. El producto debe ser
    beneficioso para la PYMEs participante y las
    PYMEs a las que va dirigido.

Criterio Umbral mínimo
Calidad CyT 4/5
Implementación 3/5
Impacto 3/5
Umbral total 12/15
29
Tiempos estimados
  • Estadio 1 debe estar finalizado en Diciembre de
    2011
  • Evaluación etapa 2 deberá ser en Marzo de 2012
  • Resultados generales se estima estarán 3 meses
    después de la fecha de cierre del llamado de
    proyectos en etapa 2.
  • Se espera que las negociaciones de los grant-
    agreements comiencen en Mayo
  • 2012.
  • Acuerdos de consorcio
  • para proyectos con financiación a partir de EUR 3
    000 000.
  • Para proyectos colaborativos con financiación
    mayor de EUR 3 000 000 el acuerdo no es
    mandatario pero sí recomendable.

30
Algunas Condiciones para los FP7-HEALTH-2012-INNOV
ATION-2
31
  • Estadio 1
  • La contribución de la UE dependerá de las
    necesidades del proyecto y no debe ser superior a
    EUR 6 000 000.
  • La duración del proyecto debe ser de hasta 3 años
  • La participación ESTA RESTRINGIDA a 3-5 entidades
    establecidas en Estados Miembro de la UE y Países
    Asociados.
  • Estadio 2
  • Los participantes incluidos las PYMEs
  • Al menos el 51 debe ser propiedad de 1 o más
    individuos que sean ciudadanos de uno de los
    Estados Miembro de la UE y Países Asociados
  • Al menos el 51 debe ser propiedad de otra
    empresa que a su vez tenga un 51 de control por
    parte de ciudadanos o residentes permanente de
    los países antes mencionados.
  • Los fondos de la UE deben ser destinados a las
    PYMEs en valores iguales o superiores a los
    especificados en la sección II.
  • La viabilidad financiera de los participantes
    será chequeada en el estadio 2 de la evaluación.
  • Los aplicantes deben presentar una propuesta
    completa con todos los detalles del plan de
    explotación, describiendo claramente la
    valorización de la tecnología a ser desarrollada.

32
Muchas gracias!
  • malvarez_at_conicet.gov.ar
Write a Comment
User Comments (0)
About PowerShow.com